Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$13.92 - $19.5 $72,537 - $101,614
-5,211 Reduced 17.14%
25,188 $376,000
Q4 2023

Feb 14, 2024

BUY
$8.37 - $19.8 $254,439 - $601,900
30,399 New
30,399 $441,000

Others Institutions Holding BMEA

About Biomea Fusion, Inc.


  • Ticker BMEA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,290,600
  • Market Cap $117M
  • Description
  • Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...
More about BMEA
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.